Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 19, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 3,280,000 ordinary shares.
- Purchase Price: 1,333.8973 pence per share.
- Treasury Shares Held: 400,002,158 shares (representing 7.11% of total voting rights).
- Shares in Issue: 5,623,518,426 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the open market purchase of 3,280,000 shares on September 19, 2007. Consequently, the total number of shares held in Treasury increased to 400,002,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Transparency Directive's transitional provision 6. No specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the total number of shares in issue (5,623,518,426) for calculating ownership thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (400,002,158) and its impact on the 7.11% voting rights representation.
- Review the Annual General Meeting minutes from May 23, 2007, to understand the full scope of the share buyback authorization.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.